In the uveal melanoma cohort, a six‐molecule signature (ARPC1B, BTBD6, GUSB, KRTCAP2, RHBDD3, and SLC39A4), which was associated with glycolysis and the immune response, was established and used for survival prediction and risk stratification of these patients.41 This evidence concerns the gene KRTCAP2 and uveal melanoma.